Trade Merrimack Pharmaceuticals, Inc. - MACK CFD
Add to favourite- Summary
- Historical Data
- Events
Spread | 0.11 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 14.71 |
Open* | 14.71 |
1-Year Change* | 21.87% |
Day's Range* | 14.7 - 14.79 |
52 wk Range | N/A |
Average Volume (10 days) | N/A |
Average Volume (3 months) | N/A |
Market Cap | N/A |
P/E Ratio | N/A |
Shares Outstanding | N/A |
Revenue | N/A |
EPS | N/A |
Dividend (Yield %) | N/A |
Beta | N/A |
Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 28, 2024 | 14.71 | -0.02 | -0.14% | 14.73 | 14.79 | 14.70 |
Mar 27, 2024 | 14.71 | 0.05 | 0.34% | 14.66 | 14.74 | 14.66 |
Mar 26, 2024 | 14.67 | -0.01 | -0.07% | 14.68 | 14.76 | 14.67 |
Mar 25, 2024 | 14.68 | 0.00 | 0.00% | 14.68 | 14.86 | 14.67 |
Mar 22, 2024 | 14.73 | 0.08 | 0.55% | 14.65 | 14.79 | 14.64 |
Mar 21, 2024 | 14.64 | -0.01 | -0.07% | 14.65 | 14.72 | 14.63 |
Mar 20, 2024 | 14.64 | 0.00 | 0.00% | 14.64 | 14.71 | 14.62 |
Mar 19, 2024 | 14.64 | -0.01 | -0.07% | 14.65 | 14.72 | 14.64 |
Mar 18, 2024 | 14.66 | 0.00 | 0.00% | 14.66 | 14.71 | 14.64 |
Mar 15, 2024 | 14.68 | 0.08 | 0.55% | 14.60 | 14.71 | 14.60 |
Mar 14, 2024 | 14.62 | -0.01 | -0.07% | 14.63 | 14.65 | 14.60 |
Mar 13, 2024 | 14.62 | 0.01 | 0.07% | 14.61 | 14.67 | 14.60 |
Mar 12, 2024 | 14.60 | -0.01 | -0.07% | 14.61 | 14.67 | 14.55 |
Mar 11, 2024 | 14.58 | -0.09 | -0.61% | 14.67 | 14.69 | 14.58 |
Mar 8, 2024 | 14.68 | 0.01 | 0.07% | 14.67 | 14.77 | 14.64 |
Mar 7, 2024 | 14.70 | 0.05 | 0.34% | 14.65 | 14.73 | 14.64 |
Mar 6, 2024 | 14.66 | 0.01 | 0.07% | 14.65 | 14.68 | 14.63 |
Mar 5, 2024 | 14.64 | -0.02 | -0.14% | 14.66 | 14.68 | 14.63 |
Mar 4, 2024 | 14.64 | -0.03 | -0.20% | 14.67 | 14.72 | 14.64 |
Mar 1, 2024 | 14.67 | 0.03 | 0.20% | 14.64 | 14.72 | 14.64 |
Merrimack Pharmaceuticals, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Merrimack Pharmaceuticals, Inc. Company profile
About Merrimack Pharmaceuticals Inc
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is entitled to receive contingent milestone payments related to its sale of ONIVYDE to Ipsen S.A. ONIVYDE is approved by the Unites States Food and Drug Administration (FDA) in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Merrimack Pharmaceuticals Inc revenues was not reported. Net loss increased 3% to $2M. Higher net loss reflects Gain on sale of assets decrease of 93% to $144K (income), Interest income decrease of 61% to $19K (income), Other income (expense), net decrease from $18K (income) to $0K. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.14 to -$0.15.
Equity composition
Common Stock $0.01 Par, 02/12, 200M auth., 94,756,679 issd. Insiders own 9.59%. IPO:TBA
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com